+ Bookmark This Page  
Preferences  |  9:33 PM
  1. Home
  2. Latest News
  3. Submit Press Release
  4. Jobs
  5. Businesses
  6. Feedback
  1. News Home
  2. News Archive
  3. By Category
  4. By Location
  5. By Date
  6. By Tag
  7. Newsletter
  8. 40,000 RSS Feeds
  9. Submit Free Press Release
 
Filter News
Category

Country

State / Province
Select Country First

City / Town
Select State First

Bharat Biotech announces the Launch of BioHib, India’s First Haemophilus Influenza type b Vaccine

India’s most pioneering biotech company, Bharat Biotech announces the launch of BioHib, India's first Haemophilus Influenza type b (Hib) vaccine. BioHib is a conjugate vaccine that has proven its safety & efficacy in multi-centric clinical trials.
 

FOR IMMEDIATE RELEASE

PRLog (Press Release)Sep 04, 2007 – Haemophilus influenza type b (Hib) bacterium causes serious disease, often life-threatening illnesses in young children. Hib can cause meningitis and severe pneumonia, leading to ~3 million cases of serious illness and 400,000 deaths each year in children under 5 years of age. Hib is difficult to treat in the developing world, with infected children in developing countries are several times worse than those in industrialized countries.  Invasive disease can be treated with antibiotics but lack of access to adequate medical facilities and increasing levels of antibiotic resistance lead to a high mortality rate: 20% of children in developing countries with Hib meningitis will die (rising to an even higher percentage in Africa and Asia). 15%- 35% of children suffering from Hib meningitis will go on to develop life long disabilities such as mental retardation or hearing loss.

The scientific and product development teams at Bharat Biotech take pride in their efforts to develop and commercialize BioHib. While other Indian manufacturers have imported conjugation and manufacturing technologies from Europe, and USA, the scientific, manufacturing and product development teams at Bharat Biotech have completely developed all processes required to manufacture BioHib in-house at Bharat Biotech.  Bharat Biotech has made significant investments to the tune of several million $ over the past 4 years, into its R&D capabilities and its manufacturing facilities to enable the development and manufacture of BioHib.

Bharat Biotech also announces the launch of its tetravalent combination vaccine, Comvac4-HB containing Diphtheria, Pertussis, Tetanus and Hepatitis B in one vaccine. These two new vaccines BioHib and Comvac4-HB, enable the deployment of a combination pentavalent vaccine in a single injection.    

“The launch of BioHib is a significant milestone for Bharat Biotech and more importantly for India, since all technologies were developed within India. BioHib has the ability to save the lives of millions of children worldwide at a very affordable price. The tetravalent and pentavalent vaccines give us the ability to protect children against multiple infectious diseases with a single injection. BioHib and Comvac4-HB are the latest offerings from Bharat Biotech in its commitment to develop safe and affordable vaccines for the developing world” said Dr. Krishna M. Ella, Chairman and Managing Director of Bharat Biotech.

# # #

About Bharat Biotech International Limited
Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotech­nology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech, established in 1996 , is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. Bharat Biotech is one of the first bio-pharma facilities in India to be audited and approved by Korean Food & Drug Administration (KFDA). Bharat Biotech sprawls over a picturesque campus at Genome Valley, Hyderabad, built with an investment of over USD 50 million. The facility's Manufacturing, Control Procedures and Protocols conform to the stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA and WHO. Bharat has set new benchmarks in innovation and quality that epitomizes the tremendous progress of Indian biotechnology in the global arena.

# # # + Share This Article Click to see PDF Version of this Press Release

Email to a Friend   Email to Author       Previous News   Next News


Issued By:Bharat Biotech International Limited
Website:http://www.bharatbiotech.com
Email:Click to contact author
Phone:91-40-23480567
Address:Genome Valley, Shameerpet
City/Town:Hyderabad
State/Province:Andhra Pradesh
Zip:500078
Country:India
Categories:Biotech
Tags:Biohib, Comvac4-hb, Haemophilus Influenzae Type B Vaccine, Combination Tetravalent Vaccine, Bharat Biotech

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog.Org can't be held liable for the contents of the press releases.   Report Abuse


Related

Esource Declares the Launch Date for India’s First Ebook Portal

Vaxin’s Pandemic Vaccine Spotlighted

New report "Booming Biotech Market in India " available through Bharatbook.com

Team Varuna joins hands with Tajen University, Taiwan

BCCL picks up stake in Manhattan Communications Private Limited


Most Viewed (Last 7 days)

One of the World’s Strongest Men Gets Violent - 3056 views

‘First Choice Joins with Bizymoms.com to educate moms about becoming a Business Broker’ - 705 views

Dee Dee Bigelow the Actress Every one is Talking About - 639 views

The Facts About GPS Technology - 439 views

Can You Survive 17 Days Without Food? - 385 views



Previous News

Next News

Are you a Journalist?


For Businesses ...


Tutorial on Free Marketing




  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Use
  5. Copyright Notice